読み込み中
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
前日終値
$53.39
+$2.95 · +5.85%
日中の時刻はETです。市場データは遅延する場合があります。
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
日中レンジ
現在 $53.39
52週レンジ
現在 $53.39
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
2
著しい割高
センチメント
68
強気
リスク
61
高リスク
モメンタム
48
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
CRISPR Therapeutics AG (CRSP) is a biotechnology firm dedicated to pioneering gene-based medicines for severe diseases. The company achieves this through its exclusive Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) technology, which enables precise and targeted alterations to an organism's genetic code. Its extensive pipeline includes therapeutic candidates spanning multiple medical areas, such as blood disorders (hemoglobinopathies), various cancers (oncology), regenerative medicine, and rare conditions. The company's flagship investigational therapy is CTX001, an ex vivo CRISPR gene-edited treatment. This therapy aims to benefit patients with transfusion-dependent beta-thalassemia or severe sickle cell disease by modifying their own hematopoietic stem cells to markedly boost the production of fetal hemoglobin within red blood cells. CRISPR Therapeutics is also advancing several other genetically engineered allogeneic (donor-sourced) CAR-T investigational therapies: CTX110, designed to combat cluster of differentiation 19-positive malignancies; CTX120, which targets B-cell maturation antigen for multiple myeloma that has relapsed or proven resistant to previous treatments; and CTX130, focused on Cluster of Differentiation 70 for a spectrum of solid tumors and blood cancers. Furthermore, the company is developing VCTX210, an immune-evasive, gene-edited stem cell-derived product candidate for treating type 1 diabetes. It is also pursuing various in vivo gene-editing initiatives aimed at addressing disorders affecting the liver, lungs, muscles, and central nervous system. The company has forged strategic alliances with significant partners, including Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was established in 2013 and maintains its headquarters in Zug, Switzerland.
日中レンジ
現在 $53.39
52週レンジ
現在 $53.39
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 351万 USD | 3500万 USD | 3.7億 USD | 43.6万 USD | 9.13億 USD |
| 売上原価 | 2.33億 USD | 1.1億 USD | 1.3億 USD | 1.1億 USD | 1.01億 USD |
| 粗利益 | −2.29億 USD | −7525万 USD | 2.4億 USD | −1.1億 USD | 8.12億 USD |
| 研究開発 | 2.65億 USD | 3.21億 USD | 3.87億 USD | 4.62億 USD | 3.41億 USD |
| 販売・一般管理 | 7354.2万 USD | 7297.7万 USD | 7616.2万 USD | 1.02億 USD | 9969万 USD |
| 営業費用 | 3.39億 USD | 3.91億 USD | 4.62億 USD | 5.63億 USD | 4.38億 USD |
| 減価償却費と償却費 | 1947.9万 USD | 1925.9万 USD | 1983.7万 USD | 2417.2万 USD | 1795.3万 USD |
| 営業利益 | −5.68億 USD | −4.67億 USD | −2.23億 USD | −6.73億 USD | 3.74億 USD |
| 純利益 | −5.82億 USD | −3.66億 USD | −1.54億 USD | −6.5億 USD | 3.78億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$67.83
上昇余地（27.05%）この株式へのエクスポージャーを報告している上場投資信託です。
ARK Innovation ETFARKK2.77億4.03%55.62億 USD0.75%$89.62+2.31%
State Street SPDR S&P Biotech ETFXBI1.39億1.41%98.74億 USD0.35%$153.77+3.00%
iShares Russell 2000 ETFIWM1.19億0.15%787.4億 USD0.19%$278.94+0.49%
ARK Genomic Revolution ETFARKG1.08億5.25%15.57億 USD0.75%$51.30+4.08%
Vanguard Extended Market ETFVXF6392.04万0.07%954億 USD0.05%$235+0.80%
iShares Biotechnology ETFIBB3509.44万0.33%108.2億 USD0.44%$206.49+3.00%
Vanguard Russell 2000 ETFVTWO3053.73万0.17%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA2591.02万0.12%218.24億 USD0.03%$32.79+0.40%ARK Innovation ETFARKKState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMARK Genomic Revolution ETFARKGVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
